Log in

AtriCure Stock Price, Forecast & Analysis (NASDAQ:ATRC)

$28.93
+0.84 (+2.99 %)
(As of 11/18/2019 02:06 AM ET)
Today's Range
$28.30
Now: $28.93
$28.98
50-Day Range
$23.90
MA: $26.53
$29.29
52-Week Range
$22.57
Now: $28.93
$34.39
Volume146,200 shs
Average Volume218,870 shs
Market Capitalization$1.14 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.27
AtriCure, Inc develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems to medical centers in the United States and internationally. The company offers Isolator Synergy and Isolator Synergy Access clamps for the treatment of persistent and long-standing persistent atrial fibrillation concomitant to other open-heart surgical procedures; EPi-Sense guided coagulation system used for the coagulation of tissue; and COBRA Fusion surgical ablation system to combine bipolar temperature-controlled radio frequency energy control with monopolar energy. Read More…

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
Current SymbolNASDAQ:ATRC
CUSIP04963C20
Phone513-755-4100

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$201.63 million
Book Value$6.53 per share

Profitability

Net Income$-21,140,000.00

Miscellaneous

Employees620
Market Cap$1.14 billion
Next Earnings Date2/27/2020 (Estimated)
OptionableOptionable

Receive ATRC News and Ratings via Email

Sign-up to receive the latest news and ratings for ATRC and its competitors with MarketBeat's FREE daily newsletter.


AtriCure (NASDAQ:ATRC) Frequently Asked Questions

What is AtriCure's stock symbol?

AtriCure trades on the NASDAQ under the ticker symbol "ATRC."

How were AtriCure's earnings last quarter?

AtriCure Inc. (NASDAQ:ATRC) released its earnings results on Wednesday, October, 30th. The medical device company reported ($0.25) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.28) by $0.03. The medical device company had revenue of $56.60 million for the quarter, compared to analysts' expectations of $55.12 million. AtriCure had a negative net margin of 10.13% and a negative return on equity of 13.59%. The company's quarterly revenue was up 13.4% on a year-over-year basis. During the same period last year, the company earned ($0.24) earnings per share. View AtriCure's Earnings History.

When is AtriCure's next earnings date?

AtriCure is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for AtriCure.

What price target have analysts set for ATRC?

5 equities research analysts have issued 12 month target prices for AtriCure's stock. Their forecasts range from $30.00 to $40.00. On average, they expect AtriCure's stock price to reach $36.20 in the next twelve months. This suggests a possible upside of 25.1% from the stock's current price. View Analyst Price Targets for AtriCure.

What is the consensus analysts' recommendation for AtriCure?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AtriCure in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for AtriCure.

Has AtriCure been receiving favorable news coverage?

Media coverage about ATRC stock has trended positive on Monday, InfoTrie Sentiment reports. InfoTrie identifies negative and positive news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. AtriCure earned a news sentiment score of 2.1 on InfoTrie's scale. They also gave press coverage about the medical device company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the immediate future. View News Stories for AtriCure.

Are investors shorting AtriCure?

AtriCure saw a drop in short interest during the month of October. As of October 31st, there was short interest totalling 822,100 shares, a drop of 37.7% from the September 30th total of 1,320,000 shares. Based on an average daily volume of 272,900 shares, the days-to-cover ratio is currently 3.0 days. Approximately 2.2% of the company's shares are short sold. View AtriCure's Current Options Chain.

Who are some of AtriCure's key competitors?

What other stocks do shareholders of AtriCure own?

Based on aggregate information from My MarketBeat watchlists, some companies that other AtriCure investors own include Amgen (AMGN), AbbVie (ABBV), Gilead Sciences (GILD), Neurocrine Biosciences (NBIX), bluebird bio (BLUE), Cellectis (CLLS), Intel (INTC), Micron Technology (MU), Abbott Laboratories (ABT) and Allergan (AGN).

Who are AtriCure's key executives?

AtriCure's management team includes the folowing people:
  • Mr. Michael H. Carrel, CEO, Pres & Director (Age 48)
  • Mr. M. Andrew Wade CPA, Sr. VP & CFO (Age 44)
  • Mr. Douglas J. Seith, Chief Operating Officer (Age 53)
  • Mr. Salvatore Privitera, Chief Technology Officer (Age 52)
  • Mr. Justin J. Noznesky, Sr. VP of Marketing & Bus. Devel. (Age 41)

Who are AtriCure's major shareholders?

AtriCure's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include GW&K Investment Management LLC (2.50%), Tamarack Advisers LP (2.15%), Peregrine Capital Management LLC (2.08%), Emerald Advisers LLC (1.11%), Eagle Asset Management Inc. (0.41%) and SG Americas Securities LLC (0.25%). Company insiders that own AtriCure stock include Douglas J Seith, Elizabeth D Krell, Justin J Noznesky, M Andrew Wade, Mark A Collar, Michael H Carrel and Regina E Groves. View Institutional Ownership Trends for AtriCure.

Which institutional investors are selling AtriCure stock?

ATRC stock was sold by a variety of institutional investors in the last quarter, including Eagle Asset Management Inc., Emerald Advisers LLC, WCM Investment Management LLC and Perkins Capital Management Inc.. Company insiders that have sold AtriCure company stock in the last year include Douglas J Seith, Justin J Noznesky, M Andrew Wade and Michael H Carrel. View Insider Buying and Selling for AtriCure.

Which institutional investors are buying AtriCure stock?

ATRC stock was acquired by a variety of institutional investors in the last quarter, including Tamarack Advisers LP, GW&K Investment Management LLC, Peregrine Capital Management LLC, SG Americas Securities LLC, Rice Hall James & Associates LLC, First Trust Advisors LP, California Public Employees Retirement System and Russell Investments Group Ltd.. View Insider Buying and Selling for AtriCure.

How do I buy shares of AtriCure?

Shares of ATRC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is AtriCure's stock price today?

One share of ATRC stock can currently be purchased for approximately $28.93.

How big of a company is AtriCure?

AtriCure has a market capitalization of $1.14 billion and generates $201.63 million in revenue each year. The medical device company earns $-21,140,000.00 in net income (profit) each year or ($0.94) on an earnings per share basis. AtriCure employs 620 workers across the globe.View Additional Information About AtriCure.

What is AtriCure's official website?

The official website for AtriCure is http://www.atricure.com/.

How can I contact AtriCure?

AtriCure's mailing address is 7555 INNOVATION WAY, MASON OH, 45040. The medical device company can be reached via phone at 513-755-4100.


MarketBeat Community Rating for AtriCure (NASDAQ ATRC)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  419 (Vote Outperform)
Underperform Votes:  304 (Vote Underperform)
Total Votes:  723
MarketBeat's community ratings are surveys of what our community members think about AtriCure and other stocks. Vote "Outperform" if you believe ATRC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ATRC will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/18/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel